新疆不同民族宫颈HPV感染现状及与Treg细胞相关性研究
|
摘要
第一部分新疆乌鲁木齐市宫颈癌HPV分型流行病学研究
目的：调查乌鲁木齐市妇女生殖道不同型别人乳头瘤病毒(HPV)的感染状况以及在人群中的分布。
方法：采用整群分层的抽样方法对乌鲁木齐市沙依巴克区18～64岁的女性开展以人群为基础的宫颈癌筛查。签署知情同意书后,对合格对象进行流行病学问卷调查。采集受试者宫颈脱落细胞,进行液基细胞学检测、HPV分型基因芯片检测。液基细胞学(LCT)检测,LCT异常者进行阴道镜及宫颈组织病理活检。以病理结果作为诊断宫颈CIN的金标准。
结果：1.该人群HPV-DNA阳性检出率为20.28%,高危型HPV阳性人群中以16、58、52和18型最多,2.高危型HPV阳性率在18～34、35～44、45～64年龄组的阳性率依次为18.07%、29.64%和7.64%(x2=105.02,P<0.05)。其中35～44岁、17～34和45～64岁三个年龄组的阳性率差异均具有显著性(χ2=19.43,P<0.05；χ2=22.62,P<0.01；χ2=66.17, P<0.01；)。3.HPV感染率随着宫颈病变的加重呈趋势性增加(x22=697.72,P<0.05；)4.外来务工人员、白领阶层、居民区人员和服务业从业妇女HPV感染率分别为24.67%,12.19%,12.74和35.11%。服务业妇女HPV感染率明显高于白领人员、居民区人员及外来务工人员(χ2=74.46,P<0.05和χ2=84.93,P<0.05；χ2=13.41,P<0.05)；而外来务工人员HPV感染率明显高于白领人员、居民区人员(x2=27.56,P<0.05和x2=29.88,P<0.05)。
结论：乌鲁木齐市HPV高危型别以16、58、52和18型最多,中年妇女是HPV高感染年龄组,不同职业中,服务业人员HPV感染率高,应加强监控。
第二部分新疆汉族、维吾尔族、哈萨克族生殖道HPV感染分型的研究
目的：调查新疆维吾尔族、汉族、哈萨克族妇女生殖道不同型别人乳头瘤病毒(HPV)的感染状况以及在人群中的分布。
方法：采用整群分层的抽样方法对新疆18～64岁的女性开展以人群为基础的宫颈癌筛查。签署知情同意书后,对合格对象进行流行病学问卷调查。采集受试者宫颈脱落细胞,进行液基细胞学检测、HPV分型基因芯片检测。液基细胞学(LCT)检测,LCT异常者进行阴道镜及宫颈组织病理活检。以病理结果作为诊断宫颈CIN的金标准。
结果：1.结婚次数,文化程度,吸烟史,人工流产数,避孕套使用,性伴数,近5年内的性伴侣数以及人群来源等与维吾尔族HPV感染相关,四个变量(文化程度、性伴侣数、避孕套使用和人群来源)进入了多因素分析模型。维吾尔族、汉族、哈萨克族比较：2.维吾尔族HPV感染率最高,与汉族、哈萨克族比较有统计学意义。3、汉族高危型HPV阳性人群中以16、58、52、18和31型HPV阳性者最多,维吾尔族高危型HPV阳性人群中以16、58、31、52和68、39型HPV阳性者最多,哈萨克族高危型HPV阳性人群中以16、18、58、33型HPV阳性者最多。4、三个民族HPV感染率随着宫颈病变的加重呈趋势性增加,三个民族C INⅡ及c INⅢ发生率比较,有统计学差异,其中维吾尔族发生率最高,与其他两组比较,均有统计学意义。
结论：文化程度和避孕套使用是HPV感染的保护因素,性伴侣数和人群来源是HPV感染的危险因素。维吾尔族HPV感染率最高,三个民族高危型HPV感染型别不同,三个民族HPV感染率随着宫颈病变的加重呈趋势性增加。
第三部分维吾尔族宫颈癌HPV与Treg免疫逃避机理的研究
目的：探讨维吾尔族宫颈癌患者外周血中CD4+CD25+CD1271o/-调节性T细胞及血清中TGF-β、IL-10及IFN-γ的表达及意义。检测维吾尔族宫颈病变不同时期以及对照组外周血CD4+CD25High Treg及其特异标志物Foxp3的表达,探讨CD4+CD25HighTreg和Foxp3在维吾尔族宫颈癌发病机制中的作用。探讨维吾尔族宫颈癌人乳头瘤病毒与CD4+CD25+CD127-调节性T细胞的相关性。
方法：采用流式细胞术检测66例维吾尔族宫颈癌患者、35例宫颈CIN Ⅱ-Ⅲ患者、45例宫颈CIN Ⅰ患者和40例正常对照组外周血中T细胞亚群、CD4+CD25+CD1271o/-Treg含量及CD4+CD25HighTreg含量,采用ELISA法检测血清中TGF-β、IFN-γ和IL-10的表达水平。并比较术前术后宫颈癌患者各组指标的变化。采用逆转录-聚合酶链反应(RT-PCR)检测CD4+CD25+T细胞中Foxp3mRNA表达水平。采用HPV (human papilloma viruse HPV)核酸扩增分型检测试剂盒检测66例维吾尔族宫颈癌患者、35例宫颈CIN(宫颈上皮内瘤样病变cervical intraepithelial neoplasia CIN)Ⅱ-Ⅲ患者、45例宫颈CINⅠ患者和40例正常对照组HPV分型。
结果：1.宫颈癌与宫颈CIN Ⅱ-Ⅲ患者外周血中CD4+CD25+CD1271o/-Treg占CD4+T淋巴细胞的百分比以及各组细胞因子的含量与宫颈CIN Ⅰ组及正常对照组比较均有统计学差异(P均<0.05)。2.宫颈癌及宫颈CIN组IFN-γ含量与CD4+CD25+CD1271o/-T reg含量呈负相关(r=-0.585, P=0.000); TGF-β、IL-10与CD4+CD25+CD127lo/-Treg含量呈正相关(r=0.690, P=0.000, r=0.827, P=0.000)。3.宫颈癌患者手术前后外周血中CD4+CD25+CD1271o/-Treg与TGF-β、IL-10及IFN-y含量的比较差异均有统计学意义(P<0.05)。4.CD4+CD25+T细胞中Foxp3mRNA表达水平,宫颈癌组与宫颈CIN I组及正常对照组比较均有统计学差异(P均<0.05)。5.宫颈癌组及宫颈CINII-III组CD4+CD25HighTreg细胞表达率与Foxp3mRNA呈显著正相关(r=0.853, P=0.000; r=0.586, P=0.000)。6. HPV与Treg显著正相关(r=0.560, P<0.05)。
结论：维吾尔族CD4+CD25+CD1271o/-Treg及相关因子TGF-β、IL-10及IFN-y及Foxp3参与了维吾尔族宫颈癌Treg免疫逃避的过程。维吾尔族宫颈癌HPV与Treg密切相关。
The first chapter Epidemic research of human papillomavirus infection genotypes of cervical cancer in Urumqi in XinJiang
Objective:To investigate the human papillomavirus infection genotypes and distribution in Urumqi Female Population reproductive tract.
Methods:A questionnaire survey was conducted among the women aged18-64years in Urumqi by randomizing clustered sampling under stratification. All of patients received liquid-based cytology test(LCT) and HPV types. The patients who had abnormal cytological diagnosis were put up digital colposcopic exam. We Used pathologic diagnosis as a gold standard to diagnose CIN.
Results:1.The positive rate of HPV was20.28%overall.2.The most prevalent genotypes of high-risk human papillomavirus (HR-HPV) were HPV16,58,52,18. The positive rate of HPV at different age groups, aged18-34,35-44,45-64years were18.07%,29.64%,7.64%, respectivly(P<0.05).3.The risk of cervical lesion significantly increased in women showing positive in cytology and HPV test. The HPV infection rate in different Occupations were different with the highest in service occupation(35.11%) while the lower appeared in works, white-collars and general residents. The HPV infection rate in works was significantly higher than that in general residents and white-collars.
Conclusion:The most prevalent genotypes of high-risk human papillomavirus (HR-HPV) were HPV16,58,52,18in Urumqi. People aged35-44years are the most frequent infected groups in Urumqi. The HPV infection rate was highest among women having service related jobs and they should be closely monitored.
The second chapter The investigation of reproductive tract human papillomavirus infection genotypes and distribution in Hans, Uygurs and Hazakhs of XinJiang
Objective:To investigate the human papillomavirus infection genotypes and distribution in Hans, Uygurs and Hazakhs of XinJiang.
Methods:A questionnaire survey was conducted among the women aged18-64years in Xinjiang by randomizing clustered sampling under stratification. All of patients received liquid-based cytology test(LCT) and HPV types. The patients who had abnormal cytological diagnosis were put up digital colposcopic exam. We Used pathologic diagnosis as a gold standard to diagnose CIN.
Results:1. Among the total,the frequency of marriage, degree of culture, smoking history, the number of induced abortion, condoms using, the NO.of sexual partner, the NO.of sexual partner in recent five years and source of population had the relevant with human papilloma-virus infection of the Uygurs. Four variables(degree of culture,the NO.of sexual partner, condoms using and source of population)had significant in the multi-factor model.2.The positive rate of HPV of Uygurs was highest.,the comparison with Hans, Hazakhs had statistical significance.3.The most prevalent genotypes of high-risk human papillomavirus (HR-HPV) of Hans were HPV16,58,52,18,31. Uygurs' were HPV16,58,31,52,68,39. Hazakhs' were HPV16,18,58,33.4. The risk of cervical lesion significantly increased in women showing positive in cytology and HPV test. The comparison of incidence of C IN Ⅱ and C INⅢ of three nations had statistical significance. Uygurs' were the highest.
Conclusion:Degree of culture and condoms using were the protect factors, the NO.of sexual partner and source of population were the risk factors. The positive rate of HPV of Uygurs was highest.The genotypes of high-risk human papillomavirus (HR-HPV) of three nations were different. The risk of cervical lesion significantly increased in women showing positive in cytology and HPV test in three nations.
The third chapter Research of mechanism of immune evasion in human papilloma viruse and CD4+CD25+CD127-Treg in cervical cancer of Uygurs
Objective:To evaluate the expressions of CD4+CD25+CD127lo/-T cells in peripheral blood and TGF-β、IL-10and IFN-γ in serum from patients of Uygurs with cervical cancer. Through detect the level of CD4+CD25High T cell and the Foxp3in peripheral blood of cervical cancer patients of Uygurs,to investigate the effect of cervical cancer pathogenesis of CD4+CD25High T cell and the Foxp3of Uygurs. To investigate the correlation between human papilloma viruse(HPV) and CD4+CD25+CD127-T cells (Treg) of Uygurs.
Methods:66patients with cervical cancer,35patients with CINII-Ⅲ,45patients with CINI and40normal controls were included in this study. The percentage of CD4+CD25+CD127lo/-T cells、CD4+CD25HighT population in CD4+T cells and T cells were evaluated by flow cytometric analysis. TGF-β、IL-10and IFN-γ were measured by ELISA.To compare the change of targets of preoperative and posto- perative of cervical cancer patients. The expression of Foxp3was evaluated by reverse transcription PCR. Typing of HPV (human papil-loma viruse) was evaluated by Nucleic acid amplification typing kit.
Results:1.The percentage of CD4+CD25+CD127lo/-T cells of CD4+T lymphocytes in peripheral blood from patients with cervical cancer and CINⅡ-Ⅲ and contents of cytokine were significantly difference in comparison with that in patients with CINI and in normal controls (P<0.05).2.The CD4+CD25+CD127lo/-T cells percentage in cervical cancer and CIN patients was negatively correlated with IFN-γ (r=-0.585, P=0.000).The CD4+CD25+CD127lo/-T cells percentage in cervical cancer and CIN patients was positive correlated with TGF-β、 IL-10(r=0.690, P=0.000, r=0.827, P=0.000).3. The percentage of CD4+CD25+CD127lo/-T cells of CD4+T lymphocytes in peripheral blood from patients with cervical cancer and contents of cytokine of preoperative were significantly difference in comparison with that in postoperative (P<0.05).4.The expression of Foxp3in CD4+CD25+T cell from patients with cervical cancer were significantly difference in comparison with that in patients with CINI and in normal controls (P<0.05).5. The CD4+CD25HighT cells percentage in cervical cancer and CINⅡ-Ⅲ patients was positive correlated with Foxp3mRNA (r=0.853, P=0.000; r=0.586, P=0.000).6. Treg was positive correlated with HPV (r=0.560, P<0.05)
Conclusion:CD4+CD25+CD1271o/-Treg, TGF-β,IL-10and IFN-y participate the process of immune evasion of cervical cancer of Uygurs. HPV was intimate correlated with Treg in cervical cancer of Uygurs.
目的：调查乌鲁木齐市妇女生殖道不同型别人乳头瘤病毒(HPV)的感染状况以及在人群中的分布。
方法：采用整群分层的抽样方法对乌鲁木齐市沙依巴克区18～64岁的女性开展以人群为基础的宫颈癌筛查。签署知情同意书后,对合格对象进行流行病学问卷调查。采集受试者宫颈脱落细胞,进行液基细胞学检测、HPV分型基因芯片检测。液基细胞学(LCT)检测,LCT异常者进行阴道镜及宫颈组织病理活检。以病理结果作为诊断宫颈CIN的金标准。
结果：1.该人群HPV-DNA阳性检出率为20.28%,高危型HPV阳性人群中以16、58、52和18型最多,2.高危型HPV阳性率在18～34、35～44、45～64年龄组的阳性率依次为18.07%、29.64%和7.64%(x2=105.02,P<0.05)。其中35～44岁、17～34和45～64岁三个年龄组的阳性率差异均具有显著性(χ2=19.43,P<0.05；χ2=22.62,P<0.01；χ2=66.17, P<0.01；)。3.HPV感染率随着宫颈病变的加重呈趋势性增加(x22=697.72,P<0.05；)4.外来务工人员、白领阶层、居民区人员和服务业从业妇女HPV感染率分别为24.67%,12.19%,12.74和35.11%。服务业妇女HPV感染率明显高于白领人员、居民区人员及外来务工人员(χ2=74.46,P<0.05和χ2=84.93,P<0.05；χ2=13.41,P<0.05)；而外来务工人员HPV感染率明显高于白领人员、居民区人员(x2=27.56,P<0.05和x2=29.88,P<0.05)。
结论：乌鲁木齐市HPV高危型别以16、58、52和18型最多,中年妇女是HPV高感染年龄组,不同职业中,服务业人员HPV感染率高,应加强监控。
第二部分新疆汉族、维吾尔族、哈萨克族生殖道HPV感染分型的研究
目的：调查新疆维吾尔族、汉族、哈萨克族妇女生殖道不同型别人乳头瘤病毒(HPV)的感染状况以及在人群中的分布。
方法：采用整群分层的抽样方法对新疆18～64岁的女性开展以人群为基础的宫颈癌筛查。签署知情同意书后,对合格对象进行流行病学问卷调查。采集受试者宫颈脱落细胞,进行液基细胞学检测、HPV分型基因芯片检测。液基细胞学(LCT)检测,LCT异常者进行阴道镜及宫颈组织病理活检。以病理结果作为诊断宫颈CIN的金标准。
结果：1.结婚次数,文化程度,吸烟史,人工流产数,避孕套使用,性伴数,近5年内的性伴侣数以及人群来源等与维吾尔族HPV感染相关,四个变量(文化程度、性伴侣数、避孕套使用和人群来源)进入了多因素分析模型。维吾尔族、汉族、哈萨克族比较：2.维吾尔族HPV感染率最高,与汉族、哈萨克族比较有统计学意义。3、汉族高危型HPV阳性人群中以16、58、52、18和31型HPV阳性者最多,维吾尔族高危型HPV阳性人群中以16、58、31、52和68、39型HPV阳性者最多,哈萨克族高危型HPV阳性人群中以16、18、58、33型HPV阳性者最多。4、三个民族HPV感染率随着宫颈病变的加重呈趋势性增加,三个民族C INⅡ及c INⅢ发生率比较,有统计学差异,其中维吾尔族发生率最高,与其他两组比较,均有统计学意义。
结论：文化程度和避孕套使用是HPV感染的保护因素,性伴侣数和人群来源是HPV感染的危险因素。维吾尔族HPV感染率最高,三个民族高危型HPV感染型别不同,三个民族HPV感染率随着宫颈病变的加重呈趋势性增加。
第三部分维吾尔族宫颈癌HPV与Treg免疫逃避机理的研究
目的：探讨维吾尔族宫颈癌患者外周血中CD4+CD25+CD1271o/-调节性T细胞及血清中TGF-β、IL-10及IFN-γ的表达及意义。检测维吾尔族宫颈病变不同时期以及对照组外周血CD4+CD25High Treg及其特异标志物Foxp3的表达,探讨CD4+CD25HighTreg和Foxp3在维吾尔族宫颈癌发病机制中的作用。探讨维吾尔族宫颈癌人乳头瘤病毒与CD4+CD25+CD127-调节性T细胞的相关性。
方法：采用流式细胞术检测66例维吾尔族宫颈癌患者、35例宫颈CIN Ⅱ-Ⅲ患者、45例宫颈CIN Ⅰ患者和40例正常对照组外周血中T细胞亚群、CD4+CD25+CD1271o/-Treg含量及CD4+CD25HighTreg含量,采用ELISA法检测血清中TGF-β、IFN-γ和IL-10的表达水平。并比较术前术后宫颈癌患者各组指标的变化。采用逆转录-聚合酶链反应(RT-PCR)检测CD4+CD25+T细胞中Foxp3mRNA表达水平。采用HPV (human papilloma viruse HPV)核酸扩增分型检测试剂盒检测66例维吾尔族宫颈癌患者、35例宫颈CIN(宫颈上皮内瘤样病变cervical intraepithelial neoplasia CIN)Ⅱ-Ⅲ患者、45例宫颈CINⅠ患者和40例正常对照组HPV分型。
结果：1.宫颈癌与宫颈CIN Ⅱ-Ⅲ患者外周血中CD4+CD25+CD1271o/-Treg占CD4+T淋巴细胞的百分比以及各组细胞因子的含量与宫颈CIN Ⅰ组及正常对照组比较均有统计学差异(P均<0.05)。2.宫颈癌及宫颈CIN组IFN-γ含量与CD4+CD25+CD1271o/-T reg含量呈负相关(r=-0.585, P=0.000); TGF-β、IL-10与CD4+CD25+CD127lo/-Treg含量呈正相关(r=0.690, P=0.000, r=0.827, P=0.000)。3.宫颈癌患者手术前后外周血中CD4+CD25+CD1271o/-Treg与TGF-β、IL-10及IFN-y含量的比较差异均有统计学意义(P<0.05)。4.CD4+CD25+T细胞中Foxp3mRNA表达水平,宫颈癌组与宫颈CIN I组及正常对照组比较均有统计学差异(P均<0.05)。5.宫颈癌组及宫颈CINII-III组CD4+CD25HighTreg细胞表达率与Foxp3mRNA呈显著正相关(r=0.853, P=0.000; r=0.586, P=0.000)。6. HPV与Treg显著正相关(r=0.560, P<0.05)。
结论：维吾尔族CD4+CD25+CD1271o/-Treg及相关因子TGF-β、IL-10及IFN-y及Foxp3参与了维吾尔族宫颈癌Treg免疫逃避的过程。维吾尔族宫颈癌HPV与Treg密切相关。
The first chapter Epidemic research of human papillomavirus infection genotypes of cervical cancer in Urumqi in XinJiang
Objective:To investigate the human papillomavirus infection genotypes and distribution in Urumqi Female Population reproductive tract.
Methods:A questionnaire survey was conducted among the women aged18-64years in Urumqi by randomizing clustered sampling under stratification. All of patients received liquid-based cytology test(LCT) and HPV types. The patients who had abnormal cytological diagnosis were put up digital colposcopic exam. We Used pathologic diagnosis as a gold standard to diagnose CIN.
Results:1.The positive rate of HPV was20.28%overall.2.The most prevalent genotypes of high-risk human papillomavirus (HR-HPV) were HPV16,58,52,18. The positive rate of HPV at different age groups, aged18-34,35-44,45-64years were18.07%,29.64%,7.64%, respectivly(P<0.05).3.The risk of cervical lesion significantly increased in women showing positive in cytology and HPV test. The HPV infection rate in different Occupations were different with the highest in service occupation(35.11%) while the lower appeared in works, white-collars and general residents. The HPV infection rate in works was significantly higher than that in general residents and white-collars.
Conclusion:The most prevalent genotypes of high-risk human papillomavirus (HR-HPV) were HPV16,58,52,18in Urumqi. People aged35-44years are the most frequent infected groups in Urumqi. The HPV infection rate was highest among women having service related jobs and they should be closely monitored.
The second chapter The investigation of reproductive tract human papillomavirus infection genotypes and distribution in Hans, Uygurs and Hazakhs of XinJiang
Objective:To investigate the human papillomavirus infection genotypes and distribution in Hans, Uygurs and Hazakhs of XinJiang.
Methods:A questionnaire survey was conducted among the women aged18-64years in Xinjiang by randomizing clustered sampling under stratification. All of patients received liquid-based cytology test(LCT) and HPV types. The patients who had abnormal cytological diagnosis were put up digital colposcopic exam. We Used pathologic diagnosis as a gold standard to diagnose CIN.
Results:1. Among the total,the frequency of marriage, degree of culture, smoking history, the number of induced abortion, condoms using, the NO.of sexual partner, the NO.of sexual partner in recent five years and source of population had the relevant with human papilloma-virus infection of the Uygurs. Four variables(degree of culture,the NO.of sexual partner, condoms using and source of population)had significant in the multi-factor model.2.The positive rate of HPV of Uygurs was highest.,the comparison with Hans, Hazakhs had statistical significance.3.The most prevalent genotypes of high-risk human papillomavirus (HR-HPV) of Hans were HPV16,58,52,18,31. Uygurs' were HPV16,58,31,52,68,39. Hazakhs' were HPV16,18,58,33.4. The risk of cervical lesion significantly increased in women showing positive in cytology and HPV test. The comparison of incidence of C IN Ⅱ and C INⅢ of three nations had statistical significance. Uygurs' were the highest.
Conclusion:Degree of culture and condoms using were the protect factors, the NO.of sexual partner and source of population were the risk factors. The positive rate of HPV of Uygurs was highest.The genotypes of high-risk human papillomavirus (HR-HPV) of three nations were different. The risk of cervical lesion significantly increased in women showing positive in cytology and HPV test in three nations.
The third chapter Research of mechanism of immune evasion in human papilloma viruse and CD4+CD25+CD127-Treg in cervical cancer of Uygurs
Objective:To evaluate the expressions of CD4+CD25+CD127lo/-T cells in peripheral blood and TGF-β、IL-10and IFN-γ in serum from patients of Uygurs with cervical cancer. Through detect the level of CD4+CD25High T cell and the Foxp3in peripheral blood of cervical cancer patients of Uygurs,to investigate the effect of cervical cancer pathogenesis of CD4+CD25High T cell and the Foxp3of Uygurs. To investigate the correlation between human papilloma viruse(HPV) and CD4+CD25+CD127-T cells (Treg) of Uygurs.
Methods:66patients with cervical cancer,35patients with CINII-Ⅲ,45patients with CINI and40normal controls were included in this study. The percentage of CD4+CD25+CD127lo/-T cells、CD4+CD25HighT population in CD4+T cells and T cells were evaluated by flow cytometric analysis. TGF-β、IL-10and IFN-γ were measured by ELISA.To compare the change of targets of preoperative and posto- perative of cervical cancer patients. The expression of Foxp3was evaluated by reverse transcription PCR. Typing of HPV (human papil-loma viruse) was evaluated by Nucleic acid amplification typing kit.
Results:1.The percentage of CD4+CD25+CD127lo/-T cells of CD4+T lymphocytes in peripheral blood from patients with cervical cancer and CINⅡ-Ⅲ and contents of cytokine were significantly difference in comparison with that in patients with CINI and in normal controls (P<0.05).2.The CD4+CD25+CD127lo/-T cells percentage in cervical cancer and CIN patients was negatively correlated with IFN-γ (r=-0.585, P=0.000).The CD4+CD25+CD127lo/-T cells percentage in cervical cancer and CIN patients was positive correlated with TGF-β、 IL-10(r=0.690, P=0.000, r=0.827, P=0.000).3. The percentage of CD4+CD25+CD127lo/-T cells of CD4+T lymphocytes in peripheral blood from patients with cervical cancer and contents of cytokine of preoperative were significantly difference in comparison with that in postoperative (P<0.05).4.The expression of Foxp3in CD4+CD25+T cell from patients with cervical cancer were significantly difference in comparison with that in patients with CINI and in normal controls (P<0.05).5. The CD4+CD25HighT cells percentage in cervical cancer and CINⅡ-Ⅲ patients was positive correlated with Foxp3mRNA (r=0.853, P=0.000; r=0.586, P=0.000).6. Treg was positive correlated with HPV (r=0.560, P<0.05)
Conclusion:CD4+CD25+CD1271o/-Treg, TGF-β,IL-10and IFN-y participate the process of immune evasion of cervical cancer of Uygurs. HPV was intimate correlated with Treg in cervical cancer of Uygurs.
引文
[1]Cruickshank ME. The role of human papillomavirus in risk management Gynaecol Practice,2003,3:2292-2331
[2]Walboomers JM, Jacobs MV, Manos MM, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J.Pathol,1999,189 (1):122-191
[3]Pilch H, Gunzel S, Schaffern U, et al. The presence of HPVDNA in cervical cancer:Correlation with clinico2pathologic parameters and prognostic signifi-cance:10 years experience atthe department of obstetrics and gynecology of the mainz university. Int JGynecol Cancer,2001,11:392-481
[4]Sakaguchi S, SakaguchiN, AsanoM, et al. Immunologic self-tolerance maintained by activated T cells exp ressing IL-2 recep tor alpha- chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol,1995,155:1151-1164
[5]Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells in.ltrating into tumor. Proc Natl Acad Sci U S A 1994; 91:3515-22.
[6]vander Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-51.
[7]Jakobisiak M, Lasek W, Golab J Natural mechanisms protecting against cancer. Immunol Lett 2003; 90(2-3):103-22.
[8]Cabrera T, Lopez-Nevot MA, Gaforio JJ, et al. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother.2003;52:1-9.
[9]Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting:from immuno-surveillance to tumor escape. Nat Immunol 2002;3(11):991-998
[10]Liu W, Putnam AL, Xu-Yu Z,et al.CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells [J].J Exp Med, 2006,203(7):1701.
[11]徐静玮,李向培,李庆,等调节性T细胞亚群变化与五种自身免疫性疾病的关系[J].中华医学检验杂志,2006,29(3)：245.
[12]Seddiki N,Santner-Nanan B,Martinson J,et al.Expression of interlenkin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells [J]. J Exp Med,2006,203(7):1693.
[13]Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4 (+) CD25(+) T cells in tumors from patients with early stage non small cell lung cancer and late stage ovarian cancer[J]. Cancer Res,2001,61 (12):4766-4772.
[14]Gray CP, Arosio P, Hersey P. Association of increased levels of heavy chain ferritin with increased CD4+CD25+regulatory T2 cell levels in patients with melanoma [J]. Clin Cancer Res,2003,9 (7):25512-2559.
[15]Kono K, Kawaida H, Takahashi A, et al. CD4 (+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers[J]. Cancer Immunol Immunother,2006,55 (9):1064-1071.
[16]Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+regulatory T cells increases during the p rogression of pancreatic ductal adenocarcinoma and its p remalignant lesions [J]. Clin Cancer Res,2006,12 (18):5423-5434.
[17]KobayashiN, HiraokaN, YamagamiW, et al. FOXP3+regulatory T cells affect the development and p rogression of hepatocarcinogenesis[J]. Clin Cancer Res,2007,13 (3):902-911.
[18]Gao Q, Qiu S J, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with p rognosis of hepatocellular carcinoma after resection [J]. J Clin Oncol,2007,25 (18):2586-2593.
[19]Font ML,Evavold BD. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. [J].Eur J Inununol,2005,35(1):76-85.
[20]He XS, Reherhann B, Boisvert J et al. Direct functional analysis of epitope-specific CD8+T cells in peripheral blood.[J]. Viral Immunol,2001,14 (1):59-69.
[21]Andrleu M, Desoutter JF, Loing E et al. Two human immunodeficiency virus vaccinal lipopoptides follow different cross-presentation pathways in human dendritic cells.[J]. J Virol,2003,77(2):1564-1570.
[22]Melief CJ, Van Der Burg SH,Toes RE et al. Efective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.[J].Immunol Rev,2002,118:177-182.
[23]郎景和.子宫颈上皮内瘤变的诊断与治疗[J].中华妇产科杂志,2001,36(5)：261-263
[24]Weinstein LC, Buchanan EM, Hillson C, et al. Screening and prevention: cervical cancer. Prim Care,2009,36(3):559-574
[25]Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine.2008,26(52):6743-6744
[26]Stevens MP, Garland SM, Tan JH, et al. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol.2009,81 (7):1283-1291
[27]Sanjose S, Diaz M, Castellsague X, Clifford G, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:a meta-analysis. Lancet Infect Dis.2007,7(7):453-459
[28]Bell MC, Schmidt-Grimminger D, There is a high prevalence of human papillo-mavirus infection in American Indian women of the Northern Plains. Gynecol Oncol.2007,(107)2:236-241
[29]李霓,代敏.中国妇女人乳头状瘤病毒感染的多中心横断面研究[J].中华疾病控制杂志,2008,12(5)：411-415.
[30]Franceschi S, Herrero R, Clifford GM,et al.Variations in the age-specific curves of human papillomavirus prevalence in women worldwide [J].Int J Cancer,2006,119 (11):2677-2684.
[31]Weinstein LC, Buchanan EM, Hillson C, et al. Screening and prevention: cervical cancer. Prim Care,2009,36(3):559-574
[32]Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillo- mavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine.2008,26(52):6743-6744
[33]李隆玉,李诚信·宫颈癌的预防及普查[J].中国实用妇科与产科杂志,2003,19(3)：151-152
[34]戎寿德,陈汶,吴令英,等.山西省襄垣县宫颈癌危险因素分析。中华预防医学杂志,2002；36(1)：41-43.
[35]曾转萍,陈凤,刘彬,等.山西省阳城县宫颈癌危险因素研究.肿瘤防治研究,2004；31(3)：178-181.
[36]陈凤,曾转萍,刘彬,等.山西省阳城县妇女人乳头瘤病毒感染的危险因素分析.实用肿瘤杂志,2004；19(4)：349-351
[37]曾转萍,陈凤,刘彬,等.山西省阳城县宫颈癌危险因素研究.肿瘤防治研究,2004；31(3)：178-181.
[38]赵方辉,马俊飞,乔友林,等.人乳头状瘤病毒DNA载量与子宫颈病变的关系.中华流行病学杂志,2004；25(11)：921-4.
[39]Zhao FH, Forman MR, Belinson J, Shen YH, Graubard BI, Patel AC, Rong SD, Pretorius RG,Qiao YL. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China. Int J Cancer. 2005 Aug 3.31
[40]Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervicalHPV infection and of CIN3 among those infected:a case-control study nested within the Manchester cohort. Br J Cancer.2000 Dec;83(11):1565-72
[41]Walboomers JM, JacobsMV, ManosMM,et al·Human papillomavirus is a necessary cause of invasive cervical can-cerworldwide [J]-JPatho,l 1999, 189(1):12-19-
[42]拉莱.苏祖克,Amy E. Noffsinger,买买提.艾力,等.新疆维吾尔族妇女子宫颈癌活检组织中人类乳头瘤病毒DNA的检测[J].中华妇产科杂志,1997,32(7)：405-408
[43]李庭芳,古力娜·库尔班,王涛,等.新疆伽师县夏普桃勒乡妇女子宫颈癌防 治研究[J].新疆医学院学报,1996,19(3)：199-203
[44]张新生,郑兴征,潘晓琳,等.新疆喀什、库尔勒及石河子地区维吾尔族妇女宫颈癌HPV16感染率对比[J].石河子大学学报(自然科学版),2005,23(3)：307-309
[45]Bosch FX, Manos MM, Munoz N,et al.Prevalence of human papillomavirus in cervical cancer:a worldwide perspective. Inter-national biological study on cervical cancer (IBSCC) study group[J].JNatl Cancer Inst,1995,87(11): 796-802.
[46]Lorincz AT, Reid R, Jenson AB,et al.Human papillomavirus infection of the cervix:relative risk associations of 15 common anogenital types [J].Obstet Gynecol,1992,79(3):328-337.
[47]Smith JS, Lindsay L, Hoots B,et al.Human papillomavirus type distribution in invasive cervical cancer and high-grade cervi-cal lesions:a meta-analysis update [J].Int JCancer,2007,121(3):621-632.
[48][48]Molano M, Van den Brule A, Plummer M,et al.Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology:a population-based,5-year follow-up study [J].Am JEpidemiol,2003, 158(5):486-494.
[49]Clifford G, Franceschi S, Diaz M,et al.Chapter 3:HPV type-distribution in women with and without cervical neoplastic diseases [J].Vaccine,2006,24 (Suppl 3):S26-S34.
[50]鲍彦平,李霓,王鹤,等.中国妇女子宫颈人乳头状瘤病毒型别分布的Meta分析[J].中华流行病学杂志,2007,28(10)：941-946.
[51]沈艳红,陈凤,黄曼妮,等.我国山西省子宫颈癌高发区HPV感染调查.中国医学科学院学报,2003；25(4)：381-385.
[52]Morgan RA, Dudley ME, Wunderlich JR, et al Cancer regression in patients after transfer of genetically engineered lymphocytes[J] Science,2006; 314 (5796):126-291
[53]Mackensen A, Meidenbauer N, Vogl S, et al Phase I study of adoptive T-cell therapy using antigen specific CD8+T cells for treatment of patients with metastatic melanoma [J] J Clin Oncol,2006; 24 (31):5060-91
[54]Meidenbauer N, Marienhagen J, Laumer M, et al Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients[J]. J Immunol,2003; 170 (4):2161-91
[55]Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ Tcells[J]. Immunology,2002; 107 (1):5291
[56]Zheng SG, Meng LZ, Wang JH, et al:Transfer of regulatory T cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+CD25+ cells in the recipient[J]. Int Immunol,2006,18:279-89
[57]Fehervari Z, Sakaguchi S:Development and function of CD25+CD4 +regulatory T cells. [J] CurrOpin Immunol,2004,16:203-208
[58]Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM et al. Ralation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening:a prospective study[J].Lancet,1999, 354(3):20
[59]程晓东,谢幸.女性人乳头瘤病毒感染的流行病学.实用妇产科杂志,2004,20(2)：65-66
[60]Belkaid Y,Piccirilo A C,et al.CD4+CD25+regulatory T cells control Leishmania major persistence and immunity.[J].Nature 2002,420:502-507.
[61]拉莱.苏祖克,Amy E. Noffsinger,买买提.艾力,等.新疆维吾尔族妇女子宫颈癌活检组织中人类乳头瘤病毒DNA的检测[J].中华妇产科杂志,1997,32(7)：405-408.
[62]Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells[J]. Nat Rev Immunol,2003,3 (3):253-257.
[63]Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3 [J]. Science,2003; 299 (5609):1057-1061.
[64]Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+T cells with regulatory properties isolated from peripheral blood [J]. J Exp Med, 2001;193(11):1285-1294.
[65]Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses [J]. Annu Rev Immunol,2004,22:531-562
[66]Takahashi T,Kuniyasu Y,Toda M. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells:induction of autoim-mune disease by breaking their anergic/suppressive state [J]. Int Immunol, 1998;10:1969-1980
[67]von Boehmer H. Mechanisms of suppression by suppressor T cells [J]. Nat Immunol,2005,6(4):338-344.
[68]Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J]. Nat Med,2004,10 (9):942-949.
[69]Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma[J]. J Immunol,2002,169 (5):2756-2761.
[70]Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma [J]. Cancer Res,2005,65 (6):2457-2464.
[71]Yang ZZ, Novak AJ, Stenson MJ, et al. Intra tumoral CD4+CD25+regulatory T cell mediated suppression of infiltrating CD4+T cells in B cell non Hodgkin lymphoma [J]. Blood,2006,107(19):3639-3646.
[72]Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25 (high) regulatory T cells are over represented in human meta-static melanoma lymph nodes and inhibit the function of infiltrating T cells [J]. J Immunol,2004,173 (2):1444-1453.
[73]Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells [J]. J Exp Med,2006,203 (7):1693-1700.
[74]Liu W, Putnam AL, Xu-Yu Z, et al. CD 127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells [J]. J Exp Med,2006,203(7):1701-1711.
[75]Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+T cells with regulatory properties isolated from peripheral blood [J]. J Exp Med, 2001;193(11):1285-1294.
[76]刘俊田,岳杰,任秀宝,等.乳腺癌患者外周血CD4+CD25+调节性T细胞的检测及意义[J].中华肿瘤杂志,2005,27：423-425
[77]Chen W, J in W, Hardegen N, et al. Conversion of peripheral CD4+ CD25-naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 [J]. J Exp Med,2003,198(12):1875-1886.
[78]Ghiringhelli F, Puig PE, Roux S, et al Tumor cells convert immature myeloid dendritic cells into TGF-β secreting cells inducing CD4+CD25+regulatory T cell proliferation[J]. J Exp Med,202(7):919-929
[79]Lundqvist A, Palmborg A, Pavlenko M, et al. Mature dendritic cells induce tumor specific type 1 regulatory T cells [J]. J Immunother,2005,28 (3): 229-235
[80]Golgher D, Jones E, Powrite F, et al.Dtpletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens[J]. Immunol,2002,32(3):3267
[81]Yagi H, Nomura T, Nakamura K, et al.Crucial role of FOXP3 in the development and function of human CD4+ CD25+ reguzatory T cells [J].Int Immunol,2004,16(11):1643
[82]Lundrgen A, Stromberg E, Sjoling A, et al.Mucosal FOXP3-Expressing CD4+CD25high Regulatory T cells in Helicobacter pylori-Infected Patients[J]. Immunity,2005,173(1):523
[83]Fontenot J D, Gavin M A, Rudensky A Y et al. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells [J].Nat Immunol,2003; 4 (4):330-336.
[84]Khattri R, Cox T, Yasayko S A et al. An essential role for Scurfin in CD4+CD25+T regulatory cells[J]. Nat Immunol,2003; 4 (4):337-342.
[85]Hori S,Nomura T, Sakaguchi S et al. Control of regulatory T cell development by the transcription factor Foxp3 [J]. Science,2003; 299(5609):1057-1061.
[86]Molling JW, de Gruijl TD, Glim J et al. CD4(+)CD25(hi) regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell response in patients with cervical intraepithelial neoplasia. [J]Int J Cancer.2007,121(8):1749-55
[87]Nakamura T, shima T, Saeki A etal.Expression of indoleamine 2, 3-dioxygenase and the recruitment of FoxP3-expressing regulatory T cells in the development and Progression of uterine cervical cancer. [J]Cancer Sci. 2007 98(6):874-881.
[88]Visser J, Nijman HW, Hoogenboom BN et al.Frequencies and role of Regulatory T cells in patients with (pre) malignant cervical neoplasia. [J] Clin ExP Immunol.2007,150(2):199-209.
[1]Zur Hausen H,Gissmann L,Steiner W, et al. Human papilloma viruses and cancer[J].Bibl Haematol,1975, (43):569-571.
[2]Pyeon D, Lambert PF, Ahlquist P. Production of infectious humanpapillo-mavirus independently of viral replication and epithelial cell differentiation [J]. Proc Natl Acad Sci USA,2005,102(26):9311-9316.
[3]Aires KA, Cianciarullo AM, Carneiro SM, et al. Production of humanpapillomavirus type 16 L1 virus-like particles by recombinantlacto-bacillus casei cells [J].Appl Environ Microbiol,2006,72(1):745-752.
[4]Burd EM. Human papilloma virus and cervical cancer [J]. ClinMicrobiol Rev, 2003,16(1):1-17.
[5]Spano JP, Marcelin AG, Carcelin G. HPV and cancer [J].Bull Cancer,2005, 92(1):59-64.
[6]Franceschi S, Herrero R, Clifford GM,et al.Variations in the age-specific curves of human papillomavirus prevalence in women worldwide [J].Int J Cancer,2006,119(11):2677-2684.
[7]Parkin DM, Bray F. Chapter 2:The burden of HPV-related can-cers [J].Vaccine, 2006,24(Suppl 3):S11-S25.
[8]Herrero R, Hildesheim A, Bratti C, et al.Population-based study of human papillomavirus infection and cervical neoplasia in rural costaRica.J Natl Cancer Inst,2000,92,464-474
[9]Infantolino C, Fabris P, Infantolino D, et al.Usefulness of humanpapilloma virus testing in the screening of cervical cancer precursor lesions:a retros-pective study in 314 cases.Eur J Obstet Gynecol Reprod Biol,2000,93:71-75.
[10]Cuzick J, Sasieni P, Davies P, et al.A systematic reviewof the role of human papillomavirus testing within a cervical screnning programme.Health Technol Assess,1999,3:1-196.
[11]Sellors JW, MahonyLB, Kaczorowski J, et al.Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ,2000, 163:503-508.
[12]Walboomer JMM, JacobsMV, Bosch FX, et al-Human papillomarvirus is a necessary cause of invasive cervical cancer worldwide.J Pathol,1999,189: 12-19.
[13]Duttagupta C, Sengupta S, Roy M, et al-Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer:a screening strategy in the perspective of rural India·Eur J Cancer Prev,2002,11:447-45
[14]Sherman ME,Wang SS,Wheeler CM,et al.Determinants of human papilloma-virus load among woman with histological cervrcal intraepithelial neoplasia 3:dominant impact of surrounding low-grade lesions [J].Cancer Epidemio Biomarkers Prev,2003,12(10):1038-1044.
[15]钱德英.高危型人乳头瘤病毒DNA检测与细胞学联合检查对宫颈癌前病变筛查研究[J].中华妇产科杂志,2006,2(1)：12-14.
[16]Sun CA,Liu JF,WU DM,et al. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions [J].Int J Gynaecol Obstet, 2002,76(1):41-47.
[17]赵爱华,张红华。多重人乳头瘤病毒感染与宫颈癌及癌前病变的相关研究。中华检验医学,2009(2)：121-124
[18]LEE SH, KANG D, SEO SS, et al. Multip le HPV infection in cervi-cal cancer screened by HPVDNA chip [J]. CancerLetter,2003,198(2):1872192.
[19]陶萍萍,卞美璐,欧华,等.导流杂交基因芯片技术在人乳头状瘤病毒检测中应用的研究[J].中华妇产科杂志,2006,41：43-47
[20]Nubia Munoz,et al.Epidemiologic classification of human papilliomavirus types associated with cervical cancer. N Engl Med 2003,348:518-527
[21]Petry KU, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany:Result for 8466 patients. BrJ Cancer, 2003,88:1570-1577.
[22]Castle PE, Schiffinan M, Burk RD, et al. Restricted cross—reactivity of hybrid capture 2 with nononcogenic human papilloma virus types. Cancer Epidemiol Biomarkers Prev,2002,11(11):1394-1399.
[23]钱德英.人乳头瘤病毒DNA检测在宫颈上皮内瘤变筛查中的价值[J].实用妇产科杂志,2004,3(20)：2.
[24]Anonymous The Betheads system for reporting cervical/vaginal cytologic diagnosis:Revised after the Second National Cancer Istitute Workshop[J].Acta Cytol,1993,37:115-124.
[25]Montz FJ, Monk BJ, Fowler JM, et al.Natural history of the minimally abnormal Papanicolaou smear[J].Obstet Gynecol,1992,80:385388
[26]Munoz N.Human papillomavirus and cancer:the epidemiological evidence[J].J Clin Virol,2000,19,15
[27]Solomon D, Schiffman M, Tarone R, et al.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance:baseline results from a randomized trial[J].J Natl Cancer Inst, 2001,93:293299
[28]Kulasingam SL, Kim JJ, Lawrence WF, et al.Costeffectiveness analysis based on the atypical squamous cells of undetermined significance/lowgrade squamous intraepithelial lesion Triage Study (ALTS)[J].J Natl Cancer Inst,2006,98:92-100
[29]丘瑾成佳景吴逸等.宫颈细胞学检查为ASCUS的临床意义及处理探讨[J]. 现代妇产科进展,2008,17(2)：85-87.
[30]周晓彬,纪新强,徐莉.医用统计学软件PPMS 1.5的组成和应用特点[J].齐鲁医学杂志,2009,24(1)：29-32.
[31]郎景和.宫颈病变的诊治[J].现代妇产科进展,2005,14(5)：341-352.
[32]周明,马小玲.宫颈上皮内瘤样变锥切术后残留/复发的研究现状[J].中国肿瘤临床,2007,34(9)：536-538.
[33]NAGAI Y, MAEHAMA T, ASATO T, et al. Persistence of human papillomavirus infection after therapeutic conization for CIN 3:is it an alarm for disease recurrence[J]. Gynecol Oncol,2000,79:294-299.
[34]初慧君,戴淑真,刘丽芝等。高危型HPV检测在宫颈病变随访中的价值.青岛大学医学院学报,2010,46(6),233-236
[35]PARASKEVAIDIS E. The role of HPV DNA testing in the folloe-upperiod after treatment for CIN:a systematic review of the tilerature[J]. Can Treat Rew, 2004,30:205.
[2]Walboomers JM, Jacobs MV, Manos MM, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J.Pathol,1999,189 (1):122-191
[3]Pilch H, Gunzel S, Schaffern U, et al. The presence of HPVDNA in cervical cancer:Correlation with clinico2pathologic parameters and prognostic signifi-cance:10 years experience atthe department of obstetrics and gynecology of the mainz university. Int JGynecol Cancer,2001,11:392-481
[4]Sakaguchi S, SakaguchiN, AsanoM, et al. Immunologic self-tolerance maintained by activated T cells exp ressing IL-2 recep tor alpha- chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol,1995,155:1151-1164
[5]Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells in.ltrating into tumor. Proc Natl Acad Sci U S A 1994; 91:3515-22.
[6]vander Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-51.
[7]Jakobisiak M, Lasek W, Golab J Natural mechanisms protecting against cancer. Immunol Lett 2003; 90(2-3):103-22.
[8]Cabrera T, Lopez-Nevot MA, Gaforio JJ, et al. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother.2003;52:1-9.
[9]Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting:from immuno-surveillance to tumor escape. Nat Immunol 2002;3(11):991-998
[10]Liu W, Putnam AL, Xu-Yu Z,et al.CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells [J].J Exp Med, 2006,203(7):1701.
[11]徐静玮,李向培,李庆,等调节性T细胞亚群变化与五种自身免疫性疾病的关系[J].中华医学检验杂志,2006,29(3)：245.
[12]Seddiki N,Santner-Nanan B,Martinson J,et al.Expression of interlenkin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells [J]. J Exp Med,2006,203(7):1693.
[13]Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4 (+) CD25(+) T cells in tumors from patients with early stage non small cell lung cancer and late stage ovarian cancer[J]. Cancer Res,2001,61 (12):4766-4772.
[14]Gray CP, Arosio P, Hersey P. Association of increased levels of heavy chain ferritin with increased CD4+CD25+regulatory T2 cell levels in patients with melanoma [J]. Clin Cancer Res,2003,9 (7):25512-2559.
[15]Kono K, Kawaida H, Takahashi A, et al. CD4 (+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers[J]. Cancer Immunol Immunother,2006,55 (9):1064-1071.
[16]Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+regulatory T cells increases during the p rogression of pancreatic ductal adenocarcinoma and its p remalignant lesions [J]. Clin Cancer Res,2006,12 (18):5423-5434.
[17]KobayashiN, HiraokaN, YamagamiW, et al. FOXP3+regulatory T cells affect the development and p rogression of hepatocarcinogenesis[J]. Clin Cancer Res,2007,13 (3):902-911.
[18]Gao Q, Qiu S J, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with p rognosis of hepatocellular carcinoma after resection [J]. J Clin Oncol,2007,25 (18):2586-2593.
[19]Font ML,Evavold BD. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. [J].Eur J Inununol,2005,35(1):76-85.
[20]He XS, Reherhann B, Boisvert J et al. Direct functional analysis of epitope-specific CD8+T cells in peripheral blood.[J]. Viral Immunol,2001,14 (1):59-69.
[21]Andrleu M, Desoutter JF, Loing E et al. Two human immunodeficiency virus vaccinal lipopoptides follow different cross-presentation pathways in human dendritic cells.[J]. J Virol,2003,77(2):1564-1570.
[22]Melief CJ, Van Der Burg SH,Toes RE et al. Efective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.[J].Immunol Rev,2002,118:177-182.
[23]郎景和.子宫颈上皮内瘤变的诊断与治疗[J].中华妇产科杂志,2001,36(5)：261-263
[24]Weinstein LC, Buchanan EM, Hillson C, et al. Screening and prevention: cervical cancer. Prim Care,2009,36(3):559-574
[25]Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine.2008,26(52):6743-6744
[26]Stevens MP, Garland SM, Tan JH, et al. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol.2009,81 (7):1283-1291
[27]Sanjose S, Diaz M, Castellsague X, Clifford G, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:a meta-analysis. Lancet Infect Dis.2007,7(7):453-459
[28]Bell MC, Schmidt-Grimminger D, There is a high prevalence of human papillo-mavirus infection in American Indian women of the Northern Plains. Gynecol Oncol.2007,(107)2:236-241
[29]李霓,代敏.中国妇女人乳头状瘤病毒感染的多中心横断面研究[J].中华疾病控制杂志,2008,12(5)：411-415.
[30]Franceschi S, Herrero R, Clifford GM,et al.Variations in the age-specific curves of human papillomavirus prevalence in women worldwide [J].Int J Cancer,2006,119 (11):2677-2684.
[31]Weinstein LC, Buchanan EM, Hillson C, et al. Screening and prevention: cervical cancer. Prim Care,2009,36(3):559-574
[32]Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillo- mavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine.2008,26(52):6743-6744
[33]李隆玉,李诚信·宫颈癌的预防及普查[J].中国实用妇科与产科杂志,2003,19(3)：151-152
[34]戎寿德,陈汶,吴令英,等.山西省襄垣县宫颈癌危险因素分析。中华预防医学杂志,2002；36(1)：41-43.
[35]曾转萍,陈凤,刘彬,等.山西省阳城县宫颈癌危险因素研究.肿瘤防治研究,2004；31(3)：178-181.
[36]陈凤,曾转萍,刘彬,等.山西省阳城县妇女人乳头瘤病毒感染的危险因素分析.实用肿瘤杂志,2004；19(4)：349-351
[37]曾转萍,陈凤,刘彬,等.山西省阳城县宫颈癌危险因素研究.肿瘤防治研究,2004；31(3)：178-181.
[38]赵方辉,马俊飞,乔友林,等.人乳头状瘤病毒DNA载量与子宫颈病变的关系.中华流行病学杂志,2004；25(11)：921-4.
[39]Zhao FH, Forman MR, Belinson J, Shen YH, Graubard BI, Patel AC, Rong SD, Pretorius RG,Qiao YL. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China. Int J Cancer. 2005 Aug 3.31
[40]Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervicalHPV infection and of CIN3 among those infected:a case-control study nested within the Manchester cohort. Br J Cancer.2000 Dec;83(11):1565-72
[41]Walboomers JM, JacobsMV, ManosMM,et al·Human papillomavirus is a necessary cause of invasive cervical can-cerworldwide [J]-JPatho,l 1999, 189(1):12-19-
[42]拉莱.苏祖克,Amy E. Noffsinger,买买提.艾力,等.新疆维吾尔族妇女子宫颈癌活检组织中人类乳头瘤病毒DNA的检测[J].中华妇产科杂志,1997,32(7)：405-408
[43]李庭芳,古力娜·库尔班,王涛,等.新疆伽师县夏普桃勒乡妇女子宫颈癌防 治研究[J].新疆医学院学报,1996,19(3)：199-203
[44]张新生,郑兴征,潘晓琳,等.新疆喀什、库尔勒及石河子地区维吾尔族妇女宫颈癌HPV16感染率对比[J].石河子大学学报(自然科学版),2005,23(3)：307-309
[45]Bosch FX, Manos MM, Munoz N,et al.Prevalence of human papillomavirus in cervical cancer:a worldwide perspective. Inter-national biological study on cervical cancer (IBSCC) study group[J].JNatl Cancer Inst,1995,87(11): 796-802.
[46]Lorincz AT, Reid R, Jenson AB,et al.Human papillomavirus infection of the cervix:relative risk associations of 15 common anogenital types [J].Obstet Gynecol,1992,79(3):328-337.
[47]Smith JS, Lindsay L, Hoots B,et al.Human papillomavirus type distribution in invasive cervical cancer and high-grade cervi-cal lesions:a meta-analysis update [J].Int JCancer,2007,121(3):621-632.
[48][48]Molano M, Van den Brule A, Plummer M,et al.Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology:a population-based,5-year follow-up study [J].Am JEpidemiol,2003, 158(5):486-494.
[49]Clifford G, Franceschi S, Diaz M,et al.Chapter 3:HPV type-distribution in women with and without cervical neoplastic diseases [J].Vaccine,2006,24 (Suppl 3):S26-S34.
[50]鲍彦平,李霓,王鹤,等.中国妇女子宫颈人乳头状瘤病毒型别分布的Meta分析[J].中华流行病学杂志,2007,28(10)：941-946.
[51]沈艳红,陈凤,黄曼妮,等.我国山西省子宫颈癌高发区HPV感染调查.中国医学科学院学报,2003；25(4)：381-385.
[52]Morgan RA, Dudley ME, Wunderlich JR, et al Cancer regression in patients after transfer of genetically engineered lymphocytes[J] Science,2006; 314 (5796):126-291
[53]Mackensen A, Meidenbauer N, Vogl S, et al Phase I study of adoptive T-cell therapy using antigen specific CD8+T cells for treatment of patients with metastatic melanoma [J] J Clin Oncol,2006; 24 (31):5060-91
[54]Meidenbauer N, Marienhagen J, Laumer M, et al Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients[J]. J Immunol,2003; 170 (4):2161-91
[55]Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ Tcells[J]. Immunology,2002; 107 (1):5291
[56]Zheng SG, Meng LZ, Wang JH, et al:Transfer of regulatory T cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+CD25+ cells in the recipient[J]. Int Immunol,2006,18:279-89
[57]Fehervari Z, Sakaguchi S:Development and function of CD25+CD4 +regulatory T cells. [J] CurrOpin Immunol,2004,16:203-208
[58]Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM et al. Ralation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening:a prospective study[J].Lancet,1999, 354(3):20
[59]程晓东,谢幸.女性人乳头瘤病毒感染的流行病学.实用妇产科杂志,2004,20(2)：65-66
[60]Belkaid Y,Piccirilo A C,et al.CD4+CD25+regulatory T cells control Leishmania major persistence and immunity.[J].Nature 2002,420:502-507.
[61]拉莱.苏祖克,Amy E. Noffsinger,买买提.艾力,等.新疆维吾尔族妇女子宫颈癌活检组织中人类乳头瘤病毒DNA的检测[J].中华妇产科杂志,1997,32(7)：405-408.
[62]Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells[J]. Nat Rev Immunol,2003,3 (3):253-257.
[63]Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3 [J]. Science,2003; 299 (5609):1057-1061.
[64]Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+T cells with regulatory properties isolated from peripheral blood [J]. J Exp Med, 2001;193(11):1285-1294.
[65]Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses [J]. Annu Rev Immunol,2004,22:531-562
[66]Takahashi T,Kuniyasu Y,Toda M. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells:induction of autoim-mune disease by breaking their anergic/suppressive state [J]. Int Immunol, 1998;10:1969-1980
[67]von Boehmer H. Mechanisms of suppression by suppressor T cells [J]. Nat Immunol,2005,6(4):338-344.
[68]Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J]. Nat Med,2004,10 (9):942-949.
[69]Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma[J]. J Immunol,2002,169 (5):2756-2761.
[70]Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma [J]. Cancer Res,2005,65 (6):2457-2464.
[71]Yang ZZ, Novak AJ, Stenson MJ, et al. Intra tumoral CD4+CD25+regulatory T cell mediated suppression of infiltrating CD4+T cells in B cell non Hodgkin lymphoma [J]. Blood,2006,107(19):3639-3646.
[72]Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25 (high) regulatory T cells are over represented in human meta-static melanoma lymph nodes and inhibit the function of infiltrating T cells [J]. J Immunol,2004,173 (2):1444-1453.
[73]Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells [J]. J Exp Med,2006,203 (7):1693-1700.
[74]Liu W, Putnam AL, Xu-Yu Z, et al. CD 127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells [J]. J Exp Med,2006,203(7):1701-1711.
[75]Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+T cells with regulatory properties isolated from peripheral blood [J]. J Exp Med, 2001;193(11):1285-1294.
[76]刘俊田,岳杰,任秀宝,等.乳腺癌患者外周血CD4+CD25+调节性T细胞的检测及意义[J].中华肿瘤杂志,2005,27：423-425
[77]Chen W, J in W, Hardegen N, et al. Conversion of peripheral CD4+ CD25-naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 [J]. J Exp Med,2003,198(12):1875-1886.
[78]Ghiringhelli F, Puig PE, Roux S, et al Tumor cells convert immature myeloid dendritic cells into TGF-β secreting cells inducing CD4+CD25+regulatory T cell proliferation[J]. J Exp Med,202(7):919-929
[79]Lundqvist A, Palmborg A, Pavlenko M, et al. Mature dendritic cells induce tumor specific type 1 regulatory T cells [J]. J Immunother,2005,28 (3): 229-235
[80]Golgher D, Jones E, Powrite F, et al.Dtpletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens[J]. Immunol,2002,32(3):3267
[81]Yagi H, Nomura T, Nakamura K, et al.Crucial role of FOXP3 in the development and function of human CD4+ CD25+ reguzatory T cells [J].Int Immunol,2004,16(11):1643
[82]Lundrgen A, Stromberg E, Sjoling A, et al.Mucosal FOXP3-Expressing CD4+CD25high Regulatory T cells in Helicobacter pylori-Infected Patients[J]. Immunity,2005,173(1):523
[83]Fontenot J D, Gavin M A, Rudensky A Y et al. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells [J].Nat Immunol,2003; 4 (4):330-336.
[84]Khattri R, Cox T, Yasayko S A et al. An essential role for Scurfin in CD4+CD25+T regulatory cells[J]. Nat Immunol,2003; 4 (4):337-342.
[85]Hori S,Nomura T, Sakaguchi S et al. Control of regulatory T cell development by the transcription factor Foxp3 [J]. Science,2003; 299(5609):1057-1061.
[86]Molling JW, de Gruijl TD, Glim J et al. CD4(+)CD25(hi) regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell response in patients with cervical intraepithelial neoplasia. [J]Int J Cancer.2007,121(8):1749-55
[87]Nakamura T, shima T, Saeki A etal.Expression of indoleamine 2, 3-dioxygenase and the recruitment of FoxP3-expressing regulatory T cells in the development and Progression of uterine cervical cancer. [J]Cancer Sci. 2007 98(6):874-881.
[88]Visser J, Nijman HW, Hoogenboom BN et al.Frequencies and role of Regulatory T cells in patients with (pre) malignant cervical neoplasia. [J] Clin ExP Immunol.2007,150(2):199-209.
[1]Zur Hausen H,Gissmann L,Steiner W, et al. Human papilloma viruses and cancer[J].Bibl Haematol,1975, (43):569-571.
[2]Pyeon D, Lambert PF, Ahlquist P. Production of infectious humanpapillo-mavirus independently of viral replication and epithelial cell differentiation [J]. Proc Natl Acad Sci USA,2005,102(26):9311-9316.
[3]Aires KA, Cianciarullo AM, Carneiro SM, et al. Production of humanpapillomavirus type 16 L1 virus-like particles by recombinantlacto-bacillus casei cells [J].Appl Environ Microbiol,2006,72(1):745-752.
[4]Burd EM. Human papilloma virus and cervical cancer [J]. ClinMicrobiol Rev, 2003,16(1):1-17.
[5]Spano JP, Marcelin AG, Carcelin G. HPV and cancer [J].Bull Cancer,2005, 92(1):59-64.
[6]Franceschi S, Herrero R, Clifford GM,et al.Variations in the age-specific curves of human papillomavirus prevalence in women worldwide [J].Int J Cancer,2006,119(11):2677-2684.
[7]Parkin DM, Bray F. Chapter 2:The burden of HPV-related can-cers [J].Vaccine, 2006,24(Suppl 3):S11-S25.
[8]Herrero R, Hildesheim A, Bratti C, et al.Population-based study of human papillomavirus infection and cervical neoplasia in rural costaRica.J Natl Cancer Inst,2000,92,464-474
[9]Infantolino C, Fabris P, Infantolino D, et al.Usefulness of humanpapilloma virus testing in the screening of cervical cancer precursor lesions:a retros-pective study in 314 cases.Eur J Obstet Gynecol Reprod Biol,2000,93:71-75.
[10]Cuzick J, Sasieni P, Davies P, et al.A systematic reviewof the role of human papillomavirus testing within a cervical screnning programme.Health Technol Assess,1999,3:1-196.
[11]Sellors JW, MahonyLB, Kaczorowski J, et al.Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ,2000, 163:503-508.
[12]Walboomer JMM, JacobsMV, Bosch FX, et al-Human papillomarvirus is a necessary cause of invasive cervical cancer worldwide.J Pathol,1999,189: 12-19.
[13]Duttagupta C, Sengupta S, Roy M, et al-Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer:a screening strategy in the perspective of rural India·Eur J Cancer Prev,2002,11:447-45
[14]Sherman ME,Wang SS,Wheeler CM,et al.Determinants of human papilloma-virus load among woman with histological cervrcal intraepithelial neoplasia 3:dominant impact of surrounding low-grade lesions [J].Cancer Epidemio Biomarkers Prev,2003,12(10):1038-1044.
[15]钱德英.高危型人乳头瘤病毒DNA检测与细胞学联合检查对宫颈癌前病变筛查研究[J].中华妇产科杂志,2006,2(1)：12-14.
[16]Sun CA,Liu JF,WU DM,et al. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions [J].Int J Gynaecol Obstet, 2002,76(1):41-47.
[17]赵爱华,张红华。多重人乳头瘤病毒感染与宫颈癌及癌前病变的相关研究。中华检验医学,2009(2)：121-124
[18]LEE SH, KANG D, SEO SS, et al. Multip le HPV infection in cervi-cal cancer screened by HPVDNA chip [J]. CancerLetter,2003,198(2):1872192.
[19]陶萍萍,卞美璐,欧华,等.导流杂交基因芯片技术在人乳头状瘤病毒检测中应用的研究[J].中华妇产科杂志,2006,41：43-47
[20]Nubia Munoz,et al.Epidemiologic classification of human papilliomavirus types associated with cervical cancer. N Engl Med 2003,348:518-527
[21]Petry KU, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany:Result for 8466 patients. BrJ Cancer, 2003,88:1570-1577.
[22]Castle PE, Schiffinan M, Burk RD, et al. Restricted cross—reactivity of hybrid capture 2 with nononcogenic human papilloma virus types. Cancer Epidemiol Biomarkers Prev,2002,11(11):1394-1399.
[23]钱德英.人乳头瘤病毒DNA检测在宫颈上皮内瘤变筛查中的价值[J].实用妇产科杂志,2004,3(20)：2.
[24]Anonymous The Betheads system for reporting cervical/vaginal cytologic diagnosis:Revised after the Second National Cancer Istitute Workshop[J].Acta Cytol,1993,37:115-124.
[25]Montz FJ, Monk BJ, Fowler JM, et al.Natural history of the minimally abnormal Papanicolaou smear[J].Obstet Gynecol,1992,80:385388
[26]Munoz N.Human papillomavirus and cancer:the epidemiological evidence[J].J Clin Virol,2000,19,15
[27]Solomon D, Schiffman M, Tarone R, et al.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance:baseline results from a randomized trial[J].J Natl Cancer Inst, 2001,93:293299
[28]Kulasingam SL, Kim JJ, Lawrence WF, et al.Costeffectiveness analysis based on the atypical squamous cells of undetermined significance/lowgrade squamous intraepithelial lesion Triage Study (ALTS)[J].J Natl Cancer Inst,2006,98:92-100
[29]丘瑾成佳景吴逸等.宫颈细胞学检查为ASCUS的临床意义及处理探讨[J]. 现代妇产科进展,2008,17(2)：85-87.
[30]周晓彬,纪新强,徐莉.医用统计学软件PPMS 1.5的组成和应用特点[J].齐鲁医学杂志,2009,24(1)：29-32.
[31]郎景和.宫颈病变的诊治[J].现代妇产科进展,2005,14(5)：341-352.
[32]周明,马小玲.宫颈上皮内瘤样变锥切术后残留/复发的研究现状[J].中国肿瘤临床,2007,34(9)：536-538.
[33]NAGAI Y, MAEHAMA T, ASATO T, et al. Persistence of human papillomavirus infection after therapeutic conization for CIN 3:is it an alarm for disease recurrence[J]. Gynecol Oncol,2000,79:294-299.
[34]初慧君,戴淑真,刘丽芝等。高危型HPV检测在宫颈病变随访中的价值.青岛大学医学院学报,2010,46(6),233-236
[35]PARASKEVAIDIS E. The role of HPV DNA testing in the folloe-upperiod after treatment for CIN:a systematic review of the tilerature[J]. Can Treat Rew, 2004,30:205.